Physician profile
Claire Ault
NPI 1710428255
$1,069.55
in general payments reported to CMS, 2019-2025
14 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $348 · 2022: $161 · 2023: $106 · 2024: $275 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.13 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $526.09 | 2021-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $194.97 | 2022-2024 | |
| Lilly USA, LLC | $71.85 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $43.33 | 2025 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $37.05 | 2025 | |
| Amgen INC. | $29.92 | 2025 | Repatha |
| Astrazeneca Pharmaceuticals LP | $28.72 | 2024 | Airsupra |
| Kowa Pharmaceuticals America, INC. | $26.95 | 2021 | |
| Novartis Pharmaceuticals Corporation | $21.64 | 2023 | |
| Exact Sciences Corporation | $20.82 | 2023 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $18.95 | 2025 | Austedo Xr |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.95 | 2025 | Jardiance |
| Edwards Lifesciences Corporation | $16.14 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Abbott Laboratories | $15.17 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claire Ault listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.